Regeneron Pharmaceuticals Inc. (REGN)

612.81
34.60 5.98
NASDAQ : Health Technology
Prev Close 578.21
Open 580.70
Day Low/High 571.52 / 615.36
52 Wk Low/High 271.37 / 583.54
Volume 6.66M
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 110.67M
Market Cap 61.35B
EPS 19.40
P/E Ratio 27.34
Div & Yield N.A. (N.A)

Latest News

Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains

Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains

Use available weakness to go long or add to longs.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room

Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform

For March and the first quarter, the RMPIA takes less of a hit than major indexes.

Jim Cramer: Here Are the Quarter's Winners, Losers

Jim Cramer: Here Are the Quarter's Winners, Losers

The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work

The drug and vaccine maker possibly could see its shares double according to a key chart.

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

Jim Cramer: The Rescue Bill and a Fed Dive-Bombing Policy Ignited All Sectors

I think our scientists, our medical minds, are working on an atomic bomb that can nuke Covid before it invades us.

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

Failed Rallies, Semiconductors Rising and the Fed's Big Guns

The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

The Fed's Big Bazooka, Covid-19 Treatments, Market Breather

Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

Regeneron Pharmaceuticals Could Be a Bright Spot in a Sea of Declines

We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.

The Magic Mice of Regeneron

The Magic Mice of Regeneron

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

Regeneron Pharmaceuticals Presents Bullish Charts Amid Covid-19 Work

The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.

5 Leading Biotechs in Search of a Coronavirus Vaccine

5 Leading Biotechs in Search of a Coronavirus Vaccine

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

This Stock Is Standing Up to the Correction Like Few Others

This Stock Is Standing Up to the Correction Like Few Others

Biotech name has bolted higher with some amazing relative strength.

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

Regeneron's Pullback Amid Market Weakness Could Lead to Buying Opportunity

The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.

Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal

Regeneron Pharmaceuticals Could Surprise on the Upside With Its Quant Buy Signal

Are the technical and quantitative approaches on the same page?

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Regeneron Has That 'Look' to It Again

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.